Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (577)	4/6/2000 11:26:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1834

1) It is certainly possible that I am wrong, but my recollection from past conversations with NBIX would lead me to believe that the backup molecules Janssen is now turning to are from the same class as R121919, developed as part of that "expanded research collaboration entered in 1999." I do not think that this sentence referred to the crosslicensing deal between NBIX/DuPont/Janssen, but to the two-year extension of the research deal between NBIX and Janssen, entered into around the same time. 2) I do know that the inhouse program molecules were described as being quite distinct from the Janssen-partnered group, so if there is any resultant 'cloud' of hepatic risk hanging over those compounds next-in-line, it is over Janssen's, not NBIX's (not that the NBIX platform is assured of safety at this point in its development.) 3)NBIX would naturally be expected to claim their retained program as superior to the one they sold, but they have been surprisingly optimistic with me about this. If so, even if the royalty deal changes with a backup, it might be a moot point. NBIX could exact a very steep toll from Janssen in order to partner the (superior) inhouse program. I realize this sounds like Pollyannish spin on a situation that was mishandled by someone, but I keep coming up with a scenario where NBIX has more leverage than it did before. NeuroInvestment (www.neuroinvestment.com)